These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28362522)

  • 21. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
    Wattjes MP; Barkhof F
    Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
    Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
    Simaniv TO; Ivanova MV; Bryukhov VV; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):98-106. PubMed ID: 31156248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
    Sahraian MA; Radue EW; Eshaghi A; Besliu S; Minagar A
    Eur J Neurol; 2012 Aug; 19(8):1060-9. PubMed ID: 22136455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Too much of a good thing? IRIS with natalizumab-associated PML.
    Berger JR
    Neurology; 2011 Sep; 77(11):1033-4. PubMed ID: 21832217
    [No Abstract]   [Full Text] [Related]  

  • 29. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ
    Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.
    Mickeviciene D; Baltusiene A; Afanasjeva B; Afanasjevas D; Gleizniene R; Rastenyte D; Berger JR
    BMC Neurol; 2022 Aug; 22(1):306. PubMed ID: 35986243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
    J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC; Hecht EM
    Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
    Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
    Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Ercan MB; Kocer B; Altiparmak T; Arslan I
    Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune reconstitution inflammatory syndrome and natalizumab-Is it possible before removing the drug?
    Mulero P; Neri MJ; Rodriguez M; Arenillas JF; Téllez N
    Mult Scler Relat Disord; 2014 Sep; 3(5):659-61. PubMed ID: 26265277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
    Wattjes MP; Vennegoor A; Mostert J; van Oosten BW; Barkhof F; Killestein J
    J Neurol; 2014 Jun; 261(6):1139-43. PubMed ID: 24705790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.